Research & University News

Investigators working for a Wellcome Trust Sanger Institute-funded study have found that patients with a particular DNA variant may experience a build-up of glutamate in nerve cell junctions of the brain, a process that is thought to lead to migraine attacks.

Location

Cancer Research Technology of the UK has signed an agreement with Bayer Schering Pharma AG to evaluate new leptin antagonist peptides as potential treatments for gynaecological diseases, including cancer.

Location

Two new approaches for treating Alzheimer’s disease have recently been disclosed. In separate announcements, a privately-owned company in Canada and researchers  in Germany have put forward different approaches for disease-modifying therapies.

Location

A new preclinical antibiotic that is being developed by GlaxoSmithKline Plc has been shown in an image fighting bacteria that are resistant to conventional antibiotics.

Location

Sanofi-Aventis SA has reportedly offered between $67 and $70 per share for Genzyme Corp in what amounts to a friendly acquisition proposal, according to a report in the 3 August 2010 edition of the Wall Street Journal.

Location

An antiretroviral-based microbicide that includes the drug, tenofovir, has been shown in a Phase 2b trial to moderately protect women against sexually-transmitted HIV. The trial results were released at an international AIDS conference in Vienna.

.

Location

BTC Plc expects to report data from a Phase 2a study of its oral multiple sclerosis treatment, Pleneva, in the first half of 2011. Meanwhile, it is making plans to take over US sales from Nycomed of two emergency care products in October, 2010.

Location

A group of international scientists has identified three monoclonal antibodies, the strongest of which neutralises more than 90% of the circulating strains of the human immunodeficiency virus (HIV). The findings were reported in the journal Science.

Location

The Global Alliance for TB Drug Development has reached an agreement with the Geneva-based Drugs for Neglected Diseases initiative (DNDi) under which it will grant royalty-free rights to DNDi to develop drugs against neglected diseases.

Location

AstraZeneca Plc and the technology transfer arm of the UK Medical Research Council have reached an agreement to share their respective compound libraries in order to increase the prospect of finding new treatments for serious diseases.

Location